Clinical Trial Update: A Phase II Safety and Tolerability Study With SEN0014196 [Phase 2]

View source ↗

Summary

Phase II safety and tolerability study of SEN0014196 for Huntington's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SEN0014196

Snippet

Sponsor: Siena Biotech S.p.A. | Conditions: Huntington's Disease | Phase 2 | Status: COMPLETED